In 2023, First Wave BioPharma, Inc., announced the initiation of its planned Phase 2 clinical trial of an enhanced enteric micro granules delivery formulation for adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) in the US.
According to MarkNtel Advisors study, The Global Exocrine Pancreatic Insufficiency (EPI) Market is estimated to grow at a CAGR of around 7.2% during the forecast period, i.e., 2024-30.
In recent years, there has been a surge in patients suffering from cystic fibrosis and other pancreatic disorders due to genetic predispositions & other lifestyle factors. These health-related concerns result in the shortage of the exocrine leading to digestion issues. Therefore, to eradicate these health issues, customers across the globe are pursuing solutions that help to fulfill the nutritive needs of the body.
Similarly, the individuals are also suffering from pancreatic cancer, which mainly concerns the pancreas of the individual. For instance, according to the Global Cancer Observatory, worldwide in 2022 there were about 511 thousand new cases of pancreatic cancer and by 2045 it will increase to 911 thousand.
Therefore, the inhabitants suffering from these deadly cancers require immediate medical intervention and undergo treatments that offer smooth functioning of the vital body organs. Further, the investigation conducted by several research associations states that the number of individuals suffering from pancreatic cancer would continue to rise. Consequently, this would further accelerate the need for different treatment options available, thereby driving the overall market for Exocrine Pancreatic Insufficiency.
✅In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.
Download Free Sample Copy @ https://www.marknteladvisors.com/query/request-sample/exocrine-pancreatic-insufficiency-market.html
Key Findings in Exocrine Pancreatic Insufficiency (EPI) Market:
|
Historical Years |
2019-2022 |
|
Base Years |
2023 |
|
Forecast Years |
2024-2030 |
|
Key Report Highlights |
· Market Dimensions & Projections · Pricing Evaluation, · Recent Strategic Moves by Companies, · Primary Stakeholders, · Analysis of Import and Export Trends, · Competitive Landscape Assessment, · Emerging Opportunities, · Market Trends and Indicators |
|
Reports Delivery Format
|
Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address. |
Exocrine Pancreatic Insufficiency (EPI) Market Key Players:
AbbVie Inc ., Nestlé, Digestive Care, Inc., Alcresta Therapeutics, Inc., Organon Group of Companies, Vivus LLC, and Others
Market Segmentation Overview:
By Treatment Method
-Pancreatic Exocrine Replacement Therapies (PERT)
-Nutritional Therapy
Among them, Pancreatic exocrine replacement therapies (PERT) hold a dominant market share in the Global Exocrine Pancreatic Insufficiency Market. These therapies follow a targeted approach that helps in addressing the underlying reason for the exocrine deficit. This consequently improves the patient’s health, thereby, garnering the interest of healthcare providers & patients, potentially driving increased adoption and market growth.
Additionally, improved symptom management and better digestion facilitated by PERT have led to reduced hospitalizations, improved nutritional status, and overall better health outcomes. These have contributed to the growing priority for Pancreatic Exocrine Replacement Therapies (PERT). As a result, the Pancreatic Exocrine Replacement Therapies (PERT) segment has witnessed significant growth.
By Distribution Channel
-Hospital Pharmacies
-Retail Pharmacies
-Online Pharmacies
Read Full Report @ https://www.marknteladvisors.com/research-library/exocrine-pancreatic-insufficiency-market.html
By Region
- North America
- South America
- Europe
- The Middle East & Africa
- Asia-Pacific
The Exocrine Pancreatic Insufficiency (EPI) Industry Recent Development:
2023: Nestlé, in partnership with enzyme engineering company Codexis, Inc., announced preliminary results from their Phase 1 study to address the limitations of current pancreatic enzyme replacement therapies (PERT).
Note: If you require specific information not covered in the current report, we can provide it through customized option
Explore Related Reports: –
About MarkNtel Advisors:
MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.
We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.
Being one of the most efficient market research companies in India, our specialized team of experienced & efficient market research professionals is capable of grasping every minute and valuable information & data of the market to offer our clients with satisfactory details. Our company has served the biggest market research firms in India at leading positions and is proficient in managing all types of market research projects.
Have an Any Query,
Call Us – US Office: +1 628 895 8081
Email – sales@marknteladvisors.com
Address Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511
Address Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India
Leave a Reply